Summit Therapeutics (MEX:SMMT) Other Current Liabilities: MXN210.52 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SMMT Summit Therapeutics Inc MEX:SMMT
30 GF Score
Price MXN290.12
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics Other Current Liabilities?

Summit Therapeutics MEX:SMMT 30 Other Current Liabilities is MXN210.52 Mil as of Jun. 2026. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Summit Therapeutics's other current liabilities for the quarter that ended in Jun. 2026 was MXN210.52 Mil.

Summit Therapeutics's quarterly other current liabilities declined from Dec. 2025 (MXN309.84 Mil) to Mar. 2026 (MXN148.25 Mil) but then increased from Mar. 2026 (MXN148.25 Mil) to Jun. 2026 (MXN210.52 Mil).

Summit Therapeutics's annual other current liabilities increased from Dec. 2023 (MXN104.32 Mil) to Dec. 2024 (MXN287.27 Mil) and increased from Dec. 2024 (MXN287.27 Mil) to Dec. 2025 (MXN309.84 Mil).

Summit Therapeutics Other Current Liabilities Related Terms

Summit Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Summit Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics Other Current Liabilities Chart

Summit Therapeutics Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103.02 122.88 104.32 287.27 309.84

Summit Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.08 237.03 309.84 148.25 210.52
MEX:SMMT
30GF Score
Summit Therapeutics Inc MEX:SMMT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Summit Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN210.52 Mil mean?
Summit Therapeutics (MEX:SMMT) has a Other Current Liabilities of MXN210.52 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Summit Therapeutics.
Is Summit Therapeutics' Other Current Liabilities too high?
Summit Therapeutics' current Other Current Liabilities is MXN210.52 Mil. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' Other Current Liabilities compare to TECH and AXSM?
Summit Therapeutics' Other Current Liabilities of MXN210.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Summit Therapeutics. Summit Therapeutics's current Other Current Liabilities is MXN210.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current Other Current Liabilities of MXN210.52 Mil. The current Other Current Liabilities is MXN210.52 Mil. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current Other Current Liabilities is MXN210.52 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:USA
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for MEX:SMMT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN290.12
Price